Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer
Status:
Unknown status
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to estimate the therapeutic efficacy of the experimental
targeted regimen including the EGFR antibody panitumumab (in combination with carboplatin and
either pegylated liposomal doxorubicin or gemcitabine) in relation to the respective standard
combination in patients with a KRAS wildtype with platinum-sensitive recurrent ovarian
cancer. It is expected that the progression free survival rate at 12 months is improved by
the targeted regimen.